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Like many other countries in Africa, Malawi is preparing 
to revise its policies for prevention of mother-to-child 
transmission (PMTCT) of HIV and for antiretroviral 
therapy (ART) in response to WHO’s 2010 guidelines.
1,2 
This guidance is timely in view of the limited eﬃ   cacy of 
single-dose nevirapine used in many PMTCT 
programmes
3 and the challenges facing the eﬀ  ective 
expansion of health service delivery.
4 The drive from the 
Global Fund to Fight AIDS, Tuberculosis and Malaria to 
increase coverage of PMTCT services is increasing, 
particularly in countries with high burdens of HIV 
infection; high coverage is essential to reduce transmission 
to infants, to provide treatment for HIV-infected women, 
and to meet the relevant 2015 Millennium Development 
Goals of reducing child mortality, improving maternal 
health, and combating HIV infection and AIDS, malaria, 
and other diseases.
The WHO guidelines specify that a CD4 cell count is 
crucial to decisions on the eligibility of HIV-infected 
pregnant women for lifelong ART. In Malawi, however, 
access to CD4 cell count analysis is minimal (panel)
5 and 
is unlikely to improve anytime soon. Thus, to make this 
test a prerequisite for increasing the coverage of PMTCT 
services and early access to ART would hinder rapid 
expansion in countries with heavily constrained health 
systems. Malawi, therefore, proposes a strategy that does 
not rely solely on CD4 cell counts but is based on the 
WHO guidelines and the public health approach outlined 
in the current Ministry of Health ART guidelines.
6 This 
strategy takes into account the weaknesses in the Malawi 
health system
7 yet should increase the coverage notably 
from the current 35%. It should also narrow the gap 
among the estimated 950  000 people living with HIV 
infection between the 225  000 currently receiving ART 
and the 440 000 who are eligible.
5,8
In HIV-infected pregnant women ART use is 
recommended when CD4 cell counts are 350 cells per μL 
or less, irrespective of WHO clinical stage, or in women 
with disease in clinical stage 3 or 4. For pregnant women 
with CD4 cell counts higher than 350 cells per μL or with 
disease at clinical stage 1 or 2 who do not yet need ART for 
their own health, WHO proposes two time-limited options 
for antiretroviral prophylaxis (table). The Ministry of 
Health in Malawi chose to use a regimen of tenofovir, 
lamuvidine, and efavirenz in these women. This regimen 
is simple, it avoids zidovudine-induced side-eﬀ  ects, 
particularly anaemia, which is a common feature of 
pregnancy in Malawi, and it will be used as the ﬁ  rst-line 
regimen in adolescents and adults. The logistics of delivery 
will be improved, the risks of running out of stocks 
lessened, the need for multiple guidelines and training 
eliminated, and the likelihood of successful implemen-
tation increased. Moreover, the proposed regimen is 
available in a ﬁ  xed-dose combination of one tablet per day, 
can be safely used with antituberculosis drugs, is eﬀ  ective 
against hepatitis B virus, and can be used without routine 
laboratory monitoring of toxic eﬀ  ects.
9
We propose to oﬀ  er all HIV-infected pregnant women 
lifelong ART. This approach is not completely new, but 
rather is a more feasible alternative to WHO’s proposed 
option B, which we call option B+. The proposed change 
is akin to the test and treat mathematical model elucidated 
by Granich and colleagues.
10 In view of the regimen’s 
good safety proﬁ  le, the diﬃ   culties involved in expansion 
of CD4 cell count testing, and the urgent need to increase 
the coverage of the PMTCT programme, we argue that 
waiting 2–3 years for the results of a pilot study would 
not be ethical. We therefore propose immediate 
implementation of this approach. If CD4 counts did 
become more accessible in Malawi, the guidelines could 
be adapted.
The expansion of the PMTCT programme in Malawi 
through implementation of option B+ would have 
various other beneﬁ  ts. The total fertility rate in Malawi 
is high, around 5·6 births per woman,
11 which is unlikely 
to be much lower in HIV-infected women.
12 Soon after 
the breastfeeding period (median duration 23 months
13) 
many women become pregnant again. Thus, a stop-start 
approach to ART administration is almost redundant. 
Many women present for antenatal care late in 
pregnancy—an estimated 50% are thought to attend 
after 28 weeks of gestation—and continuing prophylaxis 
with antiretroviral drugs would mean that the next 
pregnancy could be protected from conception. The 
stopping of ART after cessation of breastfeeding might 
lead to viral rebound, with the risk of transmission to a 
sexual partner or fetus being notably raised. Scheduled 
stopping is also diﬃ   cult to implement, as it requires 
tapering of doses to prevent drug resistance, owing to 
the diﬀ   erent half-lives of the antiretroviral drugs. 
Additionally,  the risks of opportunistic disease or 
death might be raised.
14 Tenofovir and lamuvidine are 
active against hepatitis B virus; 10–15% of people living 
with HIV infection in Malawi are also infected with 
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hepatitis B virus,
15 and reactivation of this virus is a risk 
if ART is stopped.
Universal, lifelong ART for HIV-infected pregnant 
women will achieve maximum coverage and could 
potentially lead to elimination of paediatric HIV/AIDS.
In women in Zimbabwe even those with CD4 cell 
counts higher than 350 cells per μL had a risk of death 
around six times higher than that in non-infected 
women within 24 months post partum, and early ART 
could reduce mortality by 50–90%.
16 Prevention of 
maternal deaths has a striking eﬀ  ect on child survival, 
independent of any eﬀ  ect gained from the prevention 
of HIV transmission.
The risk of developing tuberculosis increases with 
declining CD4 cell counts, from 500 cells per μL;
17 the 
majority of pregnant women have CD4 cells counts in 
this range. Early initiation of ART, therefore, reduces the 
risk of tuberculosis.
18 Observational cohort studies in the 
USA and Europe also suggest that the early starting of 
ART signiﬁ   cantly lowers mortality related to HIV 
infection and AIDS.
19
In Malawi, most HIV-infected women starting 
prophylaxis with zidovudine do so without the CD4 cell 
count being known. As about 50% of these women will 
have counts of 350 cells per μL or lower, all receive 
zidovudine monotherapy de facto. Although there is no 
evidence that exposure to zidovudine prophylaxis in 
women with advanced HIV disease increases the risk of 
drug resistance, this possibility is of concern.
HIV-transmission in couples is an important con-
tributor to overall transmission rates, and the use of ART 
greatly reduces the risk of HIV-transmission to non-HIV-
infected partners.
20
HIV status and pregnancy can be conﬁ  rmed  in 
virtually all health centres in Malawi that provide 
maternal health services. The message that triple 
therapy must be taken for life and on a daily basis from 
the start is simple. Both these features mean the 
option B+ policy could be rapidly rolled out to and 
implemented by all centres.
In the ﬁ  rst 3 years of the implementation of the option 
B+ policy we estimate that ART would be started in 
25 000 more pregnant women per year than at present; of 
note, these women would have required ART at some 
point, and are merely starting treatment earlier. To hit 
this target, the number of health facilities providing ART 
would have to increase from 377 to all 650 with mother 
and child health services. Current constraints on health 
systems and human resources will need to be addressed 
to accommodate additional burdens, such as extended 
intervals between appointments, task-shifting, and 
expansion of the health staﬀ  .
The chosen ART regimen is more expensive than a 
regimen of stavudine, lamivudine, and nevirapine 
(US$176 per person per year
21 vs $65), but we believe that 
the advantages justify the initial added cost. In addition, 
drug prices are expected to lower over time, and 
reductions in the number of infections, morbidity, and 
mortality in children and adults will contribute to a 
decline in overall treatment cost. Moreover, the 
management costs of option B+ are likely to be similar to 
those for option A or B, since the frequency of follow-up 
for mothers and infants is similar in all three. A full 
economic analysis, however, is needed.
Efavirenz is potentially teratogenic in the ﬁ  rst 
trimester, but the risk seems to be lower than previously 
thought.
22 In the absence of conclusive evidence, women 
who desire pregnancy could be oﬀ  ered an alternative 
ART regimen in which nevirapine replaces efavirenz, 
until the second trimester of the pregnancy. Other 
women receiving ART should be oﬀ  ered contraceptives 
Panel: Factors hampering universal coverage for CD4 cell count testing in Malawi
Technology
•  No easy-to-use, rapid, and reliable test (eg, dipstick technology) is currently available 
for use by health-care workers at the point of care in all health facilities
•  Reliable stocks of reagents and regular maintenance and supervision of existing CD4 
cell count equipment are diﬃ   cult to provide
•  Most equipment is currently based in tertiary and district hospitals
•  Most machines available at peripheral health facilities are still bench-top machines 
that require skilled laboratory staﬀ   to operate them
•  Various quality assurance issues remain unresolved
Health facilities 
•  The numbers of health-care workers able to do CD4 cell counts within facilities or to 
do the related administration for remote testing are limited
•  Transport of blood samples in a timely manner from all 650 health facilities in Malawi 
is cumbersome and impracticable, and samples may become unusable
•  Blood collection in tubes for transport is associated with the risk of mixing up labelling 
and results
•  Stocks of reagents frequently run out
Patients
•  The need for repeat visits to the health centre to collect results implies additional 
indirect journey costs
•  Referral of patients to diﬀ  erent clinics where CD4 cell counts can be done leads to loss 
to follow up, low uptake of referrals, or both, especially among pregnant women
WHO option A WHO option B Malawi Ministry of Health 
option B+
Mother Antepartum zidovudine 
from 14 weeks’ gestation, 
single-dose nevirapine at 
onset of labour, and 
zidovudine plus lamivudine 
during labour and delivery 
and for 7 days’ postpartum
Triple ART regimen from 
14 weeks’ gestation until 
1 week after all exposure to 
breastmilk has ended
Triple ART regimen started 
from 14 weeks’ gestation 
and taken for life
Breastfeeding 
baby
Daily nevirapine from birth 
to 1 week after all exposure 
to breastmilk has ended
Daily nevirapine syrup from 
birth to 6 weeks
Daily nevirapine from birth 
to 6 weeks
ART=antiretroviral therapy.
Table: Antiretroviral prophylaxis options recommended for HIV-infected pregnant women who do not 
need treatment for their own healthViewpoint
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in line with a comprehensive PMTCT strategy. We 
recognise that exposure to efavirenz cannot be 
completely avoided in the ﬁ  rst trimester, but this risk 
seems outweighed by increased coverage and much-
reduced overall mortality.
Our approach oﬀ  ers a real opportunity to integrate HIV 
treatment into mother and child health services and 
make tangible progress towards achieving the relevant 
Millennium Development Goals. Option B+ favours 
women rather than men in terms of ART accessibility, 
although we feel this inequality is acceptable in view of 
the policy’s potential contribution to the elimination of 
paediatric HIV infection.
The public health model outlined in this Viewpoint is 
so far untried and untested, but we are conﬁ  dent that it 
can work. Concerns about the acceptability to the general 
population of HIV testing and ART when that programme 
was scaled up in 2004 proved unfounded. Community 
acceptability for this approach would, however, have to be 
assessed from the start and human rights would have to 
be protected at all times. In the meantime, community 
leaders and health-care workers would have to be careful 
not to coerce people into being tested. National guidelines 
clearly state that everyone has the right to decline HIV 
testing without any consequences. We would expect 
community members and people living with HIV and 
AIDS to play important parts in the delivery strategy. We 
propose that sentinel sites are set up to improve human 
resources, infrastructure, and monitoring and reporting 
of drug tolerability. The people who would be responsible 
for administration of ART should be speciﬁ  ed before 
implementation.
Increasing the uptake of PMTCT linked with access to 
CD4 cell count testing has been a major challenge. 
Progress towards the relevant Millennium Development 
Goals will, therefore, depend on additional strategies to 
substantially increase PMTCT coverage. We need to 
bridge the implementation gap with a bold PMTCT 
public health approach.
6
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